About us Contacts Drug interactions: 390 212
Drug search by name

Estrasorb and Lenalidomide

Determining the interaction of Estrasorb and Lenalidomide and the possibility of their joint administration.

Check result:
Estrasorb <> Lenalidomide
Relevance: 10.06.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using lenalidomide together with estradiol may increase the risk of dangerous blood clots. The risk is higher if you are using lenalidomide with dexamethasone for the treatment of multiple myeloma than if you are using lenalidomide alone for some other condition. Also, the risk is increased with age, cigarette smoking, high blood pressure, or high cholesterol. Blood clots can lead to complications such as heart attack, pulmonary embolism (blockage of an artery in the lung), and stroke. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you experience potential signs and symptoms of blood clots such as chest pain; shortness of breath; difficulty breathing; coughing up blood; sudden loss of vision; pain, redness or swelling in an arm or leg; and numbness or weakness on one side of the body. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been observed at significantly increased rates when lenalidomide was coadministered with dexamethasone for the treatment of multiple myeloma. In two clinical trials consisting of a total of 703 multiple myeloma patients, DVT was reported as a serious or Grade 3/4 adverse drug reaction in 7.4% and 8.2% of patients in the lenalidomide/dexamethasone group (n=353), respectively, compared to 3.1% and 3.4% of patients in the placebo/dexamethasone group (n=350), respectively. Likewise, PE was reported as a serious or Grade 3/4 adverse drug reaction in 3.7% of patients in the lenalidomide/dexamethasone group versus 0.9% of patients in the placebo/dexamethasone group. Venous thromboembolic events have also been reported during lenalidomide monotherapy for the treatment of myelodysplastic syndromes.

MANAGEMENT: Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body. It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events. The decision to take prophylactic measures should be done carefully after a thorough assessment of underlying risk factors. If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy initiated. Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.

References
  • EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
  • "Product Information. Revlimid (lenalidomide)." Celgene Corporation, Summit, NJ.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
Estrasorb

Generic Name: estradiol

Brand name: Divigel, Elestrin Pump, Estrasorb, EstroGel Pump, Evamist, Alora, Climara, Estradiol Patch, Menostar, Minivelle, Vivelle-Dot, Estraderm, Vivelle, Delestrogen, Depo-Estradiol, Estrace, DepoEstradiol, Elestrin, Estradot, Estrogel, Femtrace, Femring, Gynodiol

Synonyms: n.a.

Lenalidomide

Generic Name: lenalidomide

Brand name: Revlimid

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction